Current Report Filing (8-k)
May 28 2020 - 9:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 27, 2020
AERPIO PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-38560
|
|
61-1547850
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
9987 Carver Road
Cincinnati, OH
|
|
45242
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code (513)
985-1920
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common stock, $0.0001 par value per share
|
|
ARPO
|
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 7.01.
|
Regulation FD Disclosure.
|
Aerpio Pharmaceuticals, Inc. (the Company, we or us) is furnishing a corporate presentation, attached as Exhibit 99.2 to
this Current Report on Form 8-K, which we intend to use from time to time in meetings with investors and others beginning on May 28, 2020. The corporate presentation will also be available in the investor relations section of the Companys
website at http://aerpio.com.
The information in this Item 7.01 and Exhibit 99.2 attached hereto shall not be deemed filed for purposes of
Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as
expressly set forth by specific reference in such filing.
On May 27, 2020, we issued a press release announcing the selection of razuprotafib in the I-SPY COVID-19 study, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference. Quantum Leap Healthcare Collaborative (Quantum Leap) is the sponsor of I-SPY COVID-19 TRIAL. We
have agreed to participate in the study by providing our product candidate razuprotafib for evaluation in the study. The study is a Phase 2 randomized, controlled, multicenter study with an adaptive design, and is intended to assess the therapeutic
potential of study agents, including razuprotafib, for the treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19. We will supply quantities of razuprotafib for use in the study, as
well as provide financial support totaling approximately $1.5 million.
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
AERPIO PHARMACEUTICALS, INC.
|
|
|
|
Date: May 28, 2020
|
|
By:
|
|
/s/ Joseph Gardner, Ph.D.
|
|
|
|
|
Joseph Gardner
|
|
|
|
|
President and Founder
|
Aerpio Pharmaceuticals (NASDAQ:ARPO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aerpio Pharmaceuticals (NASDAQ:ARPO)
Historical Stock Chart
From Sep 2023 to Sep 2024